文献速递血栓与止血

美国「我的生命,我们的未来」血友病基因分型计划11341名参与者的基因分析结果

Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States.
PubMed 文献 · J Thromb Haemost · 2022-07-17

「我的生命,我们的未来」是美国多部门横断面计划,2013至2017年在美国血友病治疗中心纳入11341名受试者进行血友病基因分型。多数男性患者检出变异,发现1914种独特变异,其中744种为新发现;重型血友病A中大缺失者抑制物发生率最高。

要点

  • 2013至2017年107个血友病治疗中心纳入11341名受试者,男性占68.8%、女性占31.2%。
  • 男性患者中变异检出率为血友病A 98.2%、血友病B 98.1%,共发现1914种独特变异,744种为新发现。
  • 重型血友病A中抑制物发生率最高者为大缺失(77/80),重型血友病B中为大缺失(24/42)。

核心结论

  • 「我的生命,我们的未来」是迄今规模最大的血友病基因分型项目,其结果支持血友病需要全面的基因检测方法。
  • 该工作显著促进了对血友病F8和F9基因变异及抑制物形成风险的理解。

研究设计与样本

  • 「我的生命,我们的未来」是多部门横断面美国计划,受试者和潜在遗传携带者在全美血友病治疗中心入组,由Bloodworks进行基因分型并将结果返回给提供者。
  • 临床数据取自美国血栓与止血网络数据集,社区教育由美国国家血友病基金会提供。
  • 2013至2017年,107个血友病治疗中心共纳入11341名受试者,其中男性68.8%、女性31.2%。

主要发现

  • 11341名受试者中,检测血友病A者8976名、血友病B者2358名、血友病A/B者3名、未特指血友病者4名。
  • 男性患者中变异检出率为血友病A 98.2%、血友病B 98.1%。
  • 共发现1914种独特变异(F8 1482种、F9 431种),其中744种为新发现(F8 610种、F9 134种)。
  • 6986名受试者有抑制物数据(血友病A 5583名、血友病B 1403名)。
  • 重型血友病A中抑制物发生率最高的基因型为大缺失(77/80)、复杂内含子22倒位(9/17)和未发现变异(7/14);重型血友病B中最高为大缺失(24/42)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemophilia A (HA) and hemophilia B (HB) are rare inherited bleeding disorders. Although causative genetic variants are clinically relevant, in 2012 only 20% of US patients had been genotyped. OBJECTIVES: My Life, Our Future (MLOF) was a multisector cross-sectional US initiative to improve our understanding of hemophilia through widespread genotyping. METHODS: Subjects and potential genetic carriers were enrolled at US hemophilia treatment centers (HTCs). Bloodworks performed genotyping and returned results to providers. Clinical data were abstracted from the American Thrombosis and Hemostasis Network dataset. Community education was provided by the National Hemophilia Foundation. RESULTS: From 2013 to 2017, 107 HTCs enrolled 11 341 subjects (68.8% male, 31.2% female) for testing for HA (n = 8976), HB (n = 2358), HA/HB (n = 3), and hemophilia not otherwise specified (n = 4). Variants were detected in most male patients (98.2%% HA, 98.1% HB). 1914 unique variants were found (1482 F8, 431 F9); 744 were novel (610 F8, 134 F9). Inhibitor data were available for 6986 subjects (5583 HA; 1403 HB). In severe HA, genotypes with the highest inhibitor rates were large deletions (77/80), complex intron 22 inversions (9/17), and no variant found (7/14). In severe HB, the highest rates were large deletions (24/42). Inhibitors were reported in 27.3% of Black versus 16.2% of White patients. CONCLUSIONS: The findings of MLOF are reported, the largest hemophilia genotyping project performed to date. The results support the need for comprehensive genetic approaches in hemophilia. This effort has contributed significantly towards better understanding variation in the F8 and F9 genes in hemophilia and risks of inhibitor formation.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Johnsen JM, Fletcher SN, Dove A, et al. Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. J Thromb Haemost. 2022. PMID: 35770352. doi:10.1111/jth.15805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。